SB

Sunshine Biopharma IncNASDAQ SBFM Stock Report

Last reporting period 30 Jun, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.004

Micro

Exchange

XNAS - Nasdaq

SBFM Stock Analysis

SB

Uncovered

Sunshine Biopharma Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

15/100

Low score

Market cap $B

0.004

Dividend yield

Shares outstanding

22.586 B

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company that is focused on the research, development and commercialization of oncology and antiviral drugs. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The Company’s drug development activities are focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including pancreatic cancer cells, breast cancer cells, small-cell lung cancer cells and uterine sarcoma cells. The Company, through its subsidiary, Sunshine Biopharma Canada Inc. (Sunshine Canada), develops science-based nutritional supplements. Its product includes Essential 9 a nutritional supplement tablets, which is comprised of the nine essential amino acids for human body.

View Section: Eyestock Rating